Free Trial

Robert Wasserman Analyst Performance

Analyst at StoneX

Robert Wasserman is a stock analyst at StoneX focused in the healthcare sector, covering 16 publicly traded companies. Over the past year, Robert Wasserman has issued 11 stock ratings, including buy and hold recommendations. While full access to Robert Wasserman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Robert Wasserman's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
33 Last 8 Years
Buy Recommendations
81.82% 27 Buy Ratings
Companies Covered
16 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy81.8%27 ratings
Hold18.2%6 ratings
Sell0.0%0 ratings

Out of 33 total stock ratings issued by Robert Wasserman at StoneX, the majority (81.8%) have been Buy recommendations, followed by 18.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
75.0% of companies on NASDAQ
12 companies
NYSE
18.8% of companies on NYSE
3 companies
OTCMKTS
6.3% of companies on OTCMKTS
1 company

Robert Wasserman, an analyst at StoneX, currently covers 16 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
15 companies
93.8%
Industrials
1 company
6.3%

Robert Wasserman of StoneX specializes in stock coverage within the Healthcare sector, with additional focus on Industrials companies.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
6 companies
37.5%
LIFE SCIENCES TOOLS & SERVICES
6 companies
37.5%
HEALTHCARE EQUIPMENT & SUPPLIES
1 company
6.3%
MACHINERY
1 company
6.3%
PHARMACEUTICALS
1 company
6.3%
HEALTHCARE PROVIDERS & SERVICES
1 company
6.3%

Robert Wasserman's Ratings History at StoneX

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
11/11/2026Boost Price Target$11.95$15.00Buy
Bio-Techne Corp stock logo
TECH
Bio-Techne
8/19/2026Reiterated Rating$72.51Hold
Integer Holdings Corporation stock logo
ITGR
Integer
8/13/2026Downgrade$125.33Hold
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
8/10/2026Downgrade$34.66Hold
Repligen Corporation stock logo
RGEN
Repligen
7/7/2026Upgrade$141.46$185.00Buy
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
7/7/2026Upgrade$7.87$11.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/7/2026Upgrade$649.81$185.00Buy
Proto Labs, Inc. stock logo
PRLB
Proto Labs
7/2/2026Boost Price Target$76.61$91.00Buy
Bio-Techne Corp stock logo
TECH
Bio-Techne
6/30/2026Downgrade$70.90Hold
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2/19/2026Boost Price Target$71.47$90.00Buy
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2/3/2026Reiterated Rating$75.97Buy
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
11/7/2025Boost Price Target$202.71$220.00Buy
Proto Labs, Inc. stock logo
PRLB
Proto Labs
11/3/2025Boost Price Target$49.69$55.00Buy
Integer Holdings Corporation stock logo
ITGR
Integer
10/24/2025Reiterated Rating$73.37Hold
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
9/24/2025Boost Price Target$77.57$90.00Buy
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
9/2/2025Boost Price Target$163.94$175.00Buy
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
8/20/2025Lower Price Target$7.48$37.50Speculative Buy
Bio-Techne Corp stock logo
TECH
Bio-Techne
6/5/2025Reiterated Rating$49.10$75.00Buy
OmniAb, Inc. stock logo
OABI
OmniAb
5/12/2025Reiterated Rating$1.47$6.00Buy
Bio-Techne Corp stock logo
TECH
Bio-Techne
5/8/2025Lower Price Target$48.76$75.00Buy
Integer Holdings Corporation stock logo
ITGR
Integer
4/25/2025Lower Price Target$120.27$140.00Buy
XOMA Royalty Corporation stock logo
XOMA
XOMA Royalty
4/17/2025Initiated Coverage$20.53$35.00Buy
Kamada Ltd. stock logo
KMDA
Kamada
3/21/2025Initiated Coverage$6.65$15.00Buy
OmniAb, Inc. stock logo
OABI
OmniAb
3/20/2025Lower Price Target$2.45$6.00Buy
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
3/3/2025Reiterated Rating$2.50Hold
Integer Holdings Corporation stock logo
ITGR
Integer
2/21/2025Boost Price Target$129.11$150.00Buy
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2/20/2025Reiterated Rating$57.17$75.00Buy